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ABSTRACT
Laser capture microdissection (LCM) allows the capture of cell types or well-
defined structures in tissue. We compared in a semi-quantitative way the proteomes 
from an equivalent of 8,000 tumor cells from patients with squamous cell cervical 
cancer (SCC, n = 22) with healthy epithelial and stromal cells obtained from normal 
cervical tissue (n = 13). Proteins were enzymatically digested into peptides which 
were measured by high-resolution mass spectrometry and analyzed by “all-or-
nothing” analysis, Bonferroni, and Benjamini-Hochberg correction for multiple testing. 
By comparing LCM cell type preparations, 31 proteins were exclusively found in early 
stage cervical cancer (n = 11) when compared with healthy epithelium and stroma, 
based on criteria that address specificity in a restrictive “all-or-nothing” way. By 
Bonferroni correction for multiple testing, 30 proteins were significantly up-regulated 
between early stage cervical cancer and healthy control, including six members of 
the MCM protein family. MCM proteins are involved in DNA repair and expected to be 
participating in the early stage of cancer. After a less stringent Benjamini-Hochberg 
correction for multiple testing, we found that the abundances of 319 proteins were 
significantly different between early stage cervical cancer and healthy controls. 
Four proteins were confirmed in digests of whole tissue lysates by Parallel Reaction 
Monitoring (PRM). Ingenuity Pathway Analysis using correction for multiple testing by 
permutation resulted in two networks that were differentially regulated in early stage 
cervical cancer compared with healthy tissue. From these networks, we learned that 
specific tumor mechanisms become effective during the early stage of cervical cancer. 
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INTRODUCTION
Cervical cancer is one of the most common 
cancers in women worldwide [1–3]. It is more prevalent 
in developing countries, where 83% of cases occur and 
where squamous cell cervical cancer (SCC) accounts for 
15% of newly diagnosed cancers in women. In developed 
countries, it accounts for 3.6% of all new cancer cases [4]. 
It was shown that 99% of cervical cancers are linked to 
infection with “high-risk” strains of human papillomavirus 
(HPV) [5, 6]. HPV type 16 and 18 together are responsible 
for 70% of cervical cancers [7]. HPV infections are 
associated with the development of high-grade cervical 
intraepithelial neoplasia (CIN2/3), which may eventually 
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lead to SCC [8]. It seems that the HPV E7 gene, which 
disrupts Rb function is devoid of genetic variants in 
precancer and cancer cases and strict conservation of 98 
amino acids is critical for HPV16 carcinogenesis [9]. To 
gain a deeper insight into the relation between genomic 
alterations and the development of cervical cancer, 
Ojesina et al. [10, 11] performed exome and whole 
genome sequencing and showed relationships between 
recurrent somatic mutations, copy-number alterations, 
changes in transcript levels and gene alterations as a 
consequence of HPV integration, and the development of 
cervical cancer. Whole-genome sequencing showed that 
HPV integration disrupts HPV genes as well as probably 
nearby host genes. These disruptions can lead to specific 
mechanisms in cervical cancer. Linking genomics to 
proteomics data has recently led to new insights into these 
mechanisms in cancer development [12, 13]. Laser capture 
microdissection (LCM) is a technique that allows the 
capture of different cell types or well-defined structures in 
tissue for subsequent genomics and proteomics analyses 
[14, 15]. Notably tissue from cancer patients has been 
analyzed by proteomics following this LCM technique 
[16–21]. Although this approach is very challenging due 
to the minimal amount of tissue material available for 
analysis, it was shown previously that a few hundred 
proteins can be identified from about 12,000 isolated cells 
from cervical cytological specimen [22]. We compared by 
semi-quantitative analyses the protein abundances of 4,488 
proteins based on one peptide using approximately 8,000 
cells obtained from LCM-derived cervical cancer tissue 
with healthy cervical epithelium or stroma from women 
with a normal cervix. Parallel Reaction Monitoring (PRM) 
was applied to confirm selected differential proteins found 
by the shotgun proteomics approach. Data was subjected 
to Ingenuity Pathway Analysis (IPA) linking published 
genomics data to proteomics data generated in this study. 
From the networks acquired, we learned that specific 
tumor mechanisms become effective during the early stage 
of cervical cancer. 
RESULTS 
The study included patients with squamous cell 
cervical cancer (SCC, n = 22) and controls collected from 
patients who have undergone a hysterectomy for non-
malignant reasons (n = 13) (see Table 1). 
Protein profiling by high-resolution mass 
spectrometry
By shotgun proteomics, the technical reproducibility 
of a tissue lysate digest in triplicate showed an overlap of 
identified proteins of 65%. The methodological overlap 
for three independently prepared identical LCM samples 
(performing digestion and microdissection) was 76%. 
Analysis of eleven early stage and eleven late stage SCC, 
thirteen healthy epithelium and healthy stroma samples 
by nano-LC-MS/MS resulted in a total of 2,989 identified 
proteins with a minimum number of two peptides, an FDR 
rate of 0.4% and an FDR rate of 0.04% for peptides based 
on 262,136 MS/MS spectra. On average 1,700 proteins per 
sample (1,296–2,189) were identified. Interestingly, levels 
of members of the Minichromosome Maintenance (MCM) 
family (MCM2, MCM3, MCM4, MCM5, MCM6, MCM7) 
[23, 24] were found to be highly significantly increased 
in cervical cancer tissue from early and late stage patients 
as compared to healthy tissue. A volcano plot illustrates 
the difference in abundance of proteins in the comparison 
of both early stage and late stage cervical cancer with the 
healthy epithelium (Figure 1A and 1B). 
Data were analyzed by three analysis approaches to 
find proteins which were highly discriminative (“all-or-
nothing” method, Bonferroni and a third less restrictive 
method Benjamini-Hochberg). In the most stringent 
“all-or-nothing” analysis, we searched for proteins being 
present in the early stage cervical cancer group (it was 
allowed that these proteins are presented in late stage 
cervical cancer as well) and not in healthy epithelium or 
stroma. This approach showed that 31 proteins (p < 0.05) 
were discriminative between early stage cervical cancer 
and healthy epithelium (Table 2A). With this analysis, 
only MCM4 of the MCM2-7 family was observed in early 
and late stage cervical cancer and not detectable in healthy 
epithelium and stroma cells. On the other hand, three 
proteins, ENDOU, MT-ND4 and RDH12 were exclusively 
present in healthy epithelium (in at least six out of thirteen 
samples). For stroma, six proteins TNXB, COL21A1, 
OLFML1, FMOD, HSPB6 and ABI3BP were found (in 
at least six out of thirteen samples). After correction for 
multiple testing using the Bonferroni analysis (p = 9.88 ´ 
10–6), 30 proteins (Table 2B) were significantly different 
in the comparison of early stage cervical cancer tissue and 
healthy epithelium, while thirteen proteins (Supplementary 
Table 1) were significant different between late stage 
cervical cancer tissue and healthy epithelium. Using the 
Benjamini-Hochberg correction (FDR = 5%) for multiple 
testing as the less stringent method, the abundances of 
319 proteins (Supplementary Table 2) were found to be 
significantly different between early stage cervical cancer 
and healthy epithelium. Comparison of late stage cervical 
cancer with healthy epithelium resulted in 140 proteins 
(Supplementary Table 3) having significantly different 
levels.
The IPA software tool was used to find networks in 
which the identified differentially abundant proteins might 
be involved. Fourteen out of the 30 proteins that were 
significant for early stage cervical cancer after Bonferroni 
analysis were classified to the cell cycle control network 
(“DNA Replication, Recombination, and Repair”), which 
comprises a total of 35 proteins (Figure 2) and had a 
network score of 30. This score was above the upper 
95% confidence level of the mean threshold (i.e. upper 
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95% Cl mean of 27.2) that was calculated by permutation 
from randomly taken 30 proteins of UniProt database. 
Six proteins from the network (LMNB2, MCMBP, NF-
kB complex, PCM1, RFC1, UBE2l) were identified but 
not differential by the LCM approach with at least one 
peptide. Two proteins belonging to this network (MCM5 
and WDHD1) were found by Benjamini-Hochberg 
analysis of the same data. 
The “all-or-nothing” analysis and Bonferroni 
analysis between late stage cervical cancer and healthy 
epithelium had scores below the upper 95% confidence 
level of the mean threshold (i.e. 22 < 28.9 and 8 < 11.8, 
Table 1: Overview of all squamous cervical cancer patients and healthy controls from which tissue was obtained
Sample number Age FIGO stage
Early stage cervical cancer I/II
1218 50 Ib2
1230 44 IIb
1239 43 Ib1
1291 34 Ib2
1298 80 Ib2
2110 77 IIb
2146 46 Ib2
2163 39 Ib1
2180 74 IIb
2246 73 Ib1
2252 44 Ib2
Late stage cervical cancer III/IV
1225 58 IIIb
1348 71 IIIa
1685 26 IIIb
1966 75 IVb
1981 68 IIIb
1998 72 IIIb
2008 84 IIIa
2087 49 IIIb
2247 76 IIIb
2265 83 IVb
2297 52 IVa
Healthy cervical epithelium Type 
1247 43 hypermenorrhea/meno-/metrorrhagia
1262 51 prolapse
1315 36 prolapse
1477 41 uterine leiomyoma
1516 39 dysmenorrhea
1525 41 hypermenorrhea/meno-/metrorrhagia
1542 46 prolapse
1826 45 uterine leiomyoma
1849 51 hypermenorrhea/meno-/metrorrhagia
1936 41 hypermenorrhea/meno-/metrorrhagia
1948 60 prolapse
2000 41 uterine leiomyoma
2001 49 uterine leiomyoma
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Figure 1: Differentially expressed proteins between early stage (A) and late stage (B) cervical cancer compared to healthy epithelium 
illustrated by a volcano plot. The x-axis represents the 2log fold-change and y-axis the (–)10log p-value. Examples of proteins that are 
differentially expressed with high significance are indicated with their names.
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Table 2: List of significant different proteins between early stage cervical cancer and healthy epithelium based on “all-
or-nothing principle” (A; n = 31) and after Bonferroni analysis (B; n = 30)
A. “All-or-nothing” analysis
Protein name Gene name p-value
2log fold–
change
DNA replication licensing factor MCM4 MCM4 1.92E-05 5.1
Protein S100-P S100P 3.13E-04 2.9
DNA polymerase delta catalytic subunit POLD1 3.13E-04 2.9
DnaJ homolog subfamily C member 13 DNAJC13 1.21E-03 3.4
Replication factor C subunit 2 RFC2 1.21E-03 3.4
Inactive tyrosine-protein kinase 7 PTK7 1.42E-03 2.8
Synembryn-A RIC8A 1.42E-03 2.8
Cytospin-B SPECC1 1.88E-03 2.4
U6 snRNA-associated Sm-like protein LSm2 LSM2 1.88E-03 2.4
ADP-dependent glucokinase ADPGK 1.88E-03 2.4
Eyes absent homolog 3 EYA3 1.96E-03 2.9
Polypeptide N-acetylgalactosaminyltransferase 2 GALNT2 1.99E-03 3.0
PEST proteolytic signal-containing nuclear protein PCNP 1.99E-03 3.0
HLA class II histocompatibility antigen, DRB1-16 beta chain HLA-DRB1 2.00E-03 4.2
E3 ubiquitin-protein ligase DTX3L DTX3L 3.00E-03 3.7
Importin subunit alpha-2 KPNA2 3.08E-03 3.8
CTP synthase 1 CTPS1 4.58E-03 2.6
Prolyl 3-hydroxylase 1 LEPRE1 4.58E-03 2.6
Peptidyl-tRNA hydrolase 2, mitochondrial PTRH2 4.58E-03 2.6
15 kDa selenoprotein SEP15 4.58E-03 2.6
Intercellular adhesion molecule 1 ICAM1 4.75E-03 3.6
Acyl-coenzyme A thioesterase 9, mitochondrial ACOT9 5.42E-03 3.0
Poly [ADP-ribose] polymerase 9 PARP9 5.66E-03 3.7
Nuclear pore membrane glycoprotein 210 NUP210 6.09E-03 4.0
Carcinoembryonic antigen-related cell adhesion molecule 5 CEACAM5 7.27E-03 3.8
Structural maintenance of chromosomes flexible hinge domain-containing 
protein 1 SMCHD1 1.19E-02 2.9
DBIRD complex subunit ZNF326 ZNF326 1.19E-02 2.9
E3 ubiquitin-protein ligase BRE1A RNF20 1.43E-02 2.8
Mitochondrial Rho GTPase 2 RHOT2 1.43E-02 2.8
Sterile alpha motif domain-containing protein 9 SAMD9 2.17E-02 3.8
Myeloperoxidase MPO 3.96E-02 5.0
B. Bonferroni correction for multiple testing
Protein name Gene name p-value
2log fold–
change
Keratin, type I cytoskeletal 13* KRT13 1.50E-09 –2.6
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respectively) and for this reason the created networks 
were not further investigated. On the other hand, for the 
Benjamini-Hochberg analysis two networks (i.e. “DNA 
Replication, Recombination, and Repair” and “Cardiac 
Arrhythmia, Cardiovascular Disease, Organismal 
Injury and Abnormalities”; see Figure 3 and Figure 
4, respectively) were found with an identical score 
that passed the threshold (i.e. 43 > 41.4). For the other 
group, comparing late stage cervical cancer with healthy 
epithelium one network (also related to “DNA Replication, 
Recombination, and Repair”; see Figure 5) identified by 
the Benjamini-Hochberg analysis exceeded the threshold 
score of 40.8 (i.e. 48 > 40.8). Proteins indicated in the 
“DNA Replication, Recombination, and Repair” network 
identified by IPA (i.e. Figure 2, Bonferroni analysis; 
Figure 3 and 5, Benjamini-Hochberg analysis) showed an 
overlap close to 30% of all network proteins mentioned. 
The other network (“Cardiac Arrhythmia, Cardiovascular 
Envoplakin EVPL 1.18E-07 –1.9
Cornulin* CRNN 1.37E-07 –4.6
Desmocollin-2* DSC2 4.47E-07 –1.7
Acidic leucine-rich nuclear phosphoprotein 32 family member A ANP32A 1.57E-06 1.4
DNA topoisomerase 1 TOP1 6.56E-06 2.1
Protein disulfide-isomerase TMX3 TMX3 1.13E-05 2.0
Protein disulfide-isomerase A3 PDIA3 1.42E-05 0.7
DNA replication licensing factor MCM4 MCM4 1.92E-05 5.1
DNA replication licensing factor MCM6* MCM6 1.95E-05 3.0
DNA replication licensing factor MCM7* MCM7 2.04E-05 3.6
Desmoglein-1 DSG1 2.12E-05 –2.9
Ribosome-binding protein 1 RRBP1 2.15E-05 1.4
Exportin-2 CSE1L 2.45E-05 1.2
DNA replication licensing factor MCM3 MCM3 2.68E-05 4.3
Heterogeneous nuclear ribonucleoproteins A2/B1 HNRNPA2B1 3.31E-05 1.0
Keratin, type II cytoskeletal 5 KRT5 3.55E-05 –1.0
78 kDa glucose-regulated protein HSPA5 3.60E-05 0.8
Calreticulin CALR 4.23E-05 1.5
Nucleoprotein TPR TPR 4.28E-05 1.8
DNA replication licensing factor MCM2 MCM2 5.24E-05 4.9
Endoplasmic reticulum resident protein 29* ERP29 7.93E-05 1.8
Nuclear pore complex protein Nup155 NUP155 9.16E-05 1.9
Phospholipase A-2-activating protein PLAA 1.15E-04 3.2
Flap endonuclease 1* FEN1 1.49E-04 2.7
Tryptophan--tRNA ligase, cytoplasmic WARS 1.90E-04 3.0
Pre-mRNA-processing factor 6 PRPF6 2.99E-04 3.2
Protein S100-P S100P 3.13E-04 2.9
DNA polymerase delta catalytic subunit POLD1 3.13E-04 2.9
Serpin H1 SERPINH1 3.30E-04 3.7
Zero counts were converted to 0.125 to enable log calculations. Supplementary Table 1 shows a complete list of proteins 
assigned to late stage cervical cancer analyzed by Bonferroni analysis (here indicated with an asterisk (*)) and individual 
comparison of early and late stage cervical cancer with healthy epithelium using Benjamini-Hochberg as shown in 
Supplementary Tables 2 and 3, respectively.
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Disease, Organismal Injury and Abnormalities”, Figure 4) 
consisted of almost 50% of down-regulated proteins that 
did not show any overlap with the first network mentioned 
(Figure 3). An overview of the different analyses achieved 
by comparison of individual early and late stage cervical 
cancer with healthy epithelium is displayed in Table 3.
Hierarchical clustering of the differentially abundant 
fourteen proteins found in the “DNA, Replication, 
Recombination and Repair Network” by IPA analysis of 
the Bonferroni analysis resulted in clusters of proteins 
showing similarities between the early and late stage 
cervical cancer, while for the healthy epithelium group 
this was significantly different (Figure 6). 
Protein profiles in early stage cervical cancer tissue 
by LCM with HeLa, U87 and HEK293 cell lines
From the 31 proteins (Table 2A) that were 
exclusively found by the “all-or-nothing” analysis in early 
stage cervical cancer and that all meet an extra criterion: 
2log fold-change > 1, 30 were up-regulated in late stage 
cervical cancer tissue, 24 in the HeLa cell line, eleven in 
U87 and nine in HEK293 cells. From the 30 significantly 
different proteins selected after using Bonferroni analysis 
(Table 2B), according to identical criterion as mentioned 
above, 22 were up-regulated in both early stage cervical 
cancer and in the HeLa cell line and nineteen in late stage 
Figure 2: Ingenuity pathway analysis (IPA) of the 30 significantly up- and down-regulated proteins (after Bonferroni 
analysis) for early stage cervical cancer versus healthy controls. Pathway analysis indicated that the network “DNA Replication, 
Recombination, and Repair”, containing fourteen out of the 30 significant proteins, is up-regulated. The network itself consists of 35 
proteins. The up-regulated proteins in early stage cervical cancer are marked red, while those that that were down-regulated were not 
identified in this pathway. The intensity of the color relates to fold-change. Proteins indicated with a red asterisk were found by LCM, 
although not differential. Benjamini-Hochberg analysis of the same data resulted in two more proteins (encircled in purple) belonging to 
this network (MCM5 and WDHD1). The symbols shown in the network are explained at http://www.qiagenbioinformatics.com/products/
ingenuity-pathway-analysis.
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cervical cancer tissue. Fifteen out of the 30 significantly 
different proteins were up-regulated in the U87 cell line, 
while fourteen proteins were up-regulated in HEK293 cells. 
From the 319 significantly different proteins selected after 
using Benjamini-Hochberg correction (Supplementary 
Table 2) using identical criterion, 249 were up-regulated 
in early stage cervical cancer, 210 in the late stage cervical 
cancer, 244 in the HeLa cell line, 163 in the U87 cell line 
and 109 were up-regulated in the HEK293 cell line.
Three out of the 35 proteins (Figure 2) that were 
related to the network “DNA Replication, Recombination, 
and Repair” were significantly up-regulated (2log fold-
change > 1) in both early and late stage cervical cancer 
and in the HeLa cell line compared to healthy epithelium 
(NF-κB complex, PLAA, POLD1, S100P and WDHD1), 
but were absent in the other two cell lines (U87 and 
HEK293). In Figure 7, the presence or absence of the 
differential proteins found by Bonferroni analysis only 
Figure 3: The 319 significantly proteins (up- and down-regulated) that were found by Benjamini-Hochberg analysis 
for early stage cervical cancer were applied to the IPA analysis tool. The pathway analysis resulted in two networks with 
identical scores that passed the threshold. The indicated network matched to “DNA Replication, Recombination, and Repair” containing 
29 out of the 319 significant proteins. The network itself consists of 35 proteins. The up-regulated proteins in early stage cervical cancer 
are marked red, while those that that were down-regulated were not identified in this pathway. The intensity of the color relates to fold-
change. The NF-κB complex protein indicated with a red asterisk was identified once (99% protein- and 95% peptide probability with at 
least one peptide) by LCM, although not differential. The second network that passed the permutation background score is represented in 
Figure 4. The symbols shown in the network are explained at http://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis.
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related to this network observed in early and late stage 
cervical cancer is illustrated. 
Furthermore, comparison of results derived from all 
proteins identified with LCM-derived tumor cells from 
early and late stage cervical cancer and HeLa cell line 
(following criterion: 2log fold-change relative to healthy 
epithelium ≥2.5), with non-cervical U87 and HEK293 cell 
lines showed nineteen highly significantly up-regulated 
proteins. Following the same criterion, fourteen proteins 
were found to be exclusively discriminative for the LCM 
dissected tumor cells only (Table 4).
Quantification of MCM3, CEACAM5, S100P 
and ICAM1 in whole tissue lysates by PRM
The concentrations of four proteins, MCM3, 
CEACAM5, S100P and ICAM1, that were highly 
significant in cervical cancer tissue found by the shotgun 
approach of each sample are represented in Supplementary 
Excel Data File 1. The PRM data have been deposited to 
the ProteomeXchange Consortium via the PRIDE [25] 
partner repository with the dataset identifier PXD008723 
and 10.6019/PXD008723. An example of the calculated 
concentrations of the four targeted proteins by PRM is 
illustrated in Figure 8. Linearity, LOD (limit of detection), 
LOQ (limit of quantification) and reproducibility of serial 
dilutions of SIL peptide standards are represented in 
Supplementary Excel Data File 2.
Comparison of protein profiles with 
transcriptome data
All proteins of the “all-or-nothing” and Bonferroni 
analyses (n = 55, which were commonly and exclusively 
found for both analyses, see Table 2A and 2B, respectively) 
were observed as relative high gene expression levels 
Figure 4: The second network with identical score as shown in previous network (Figure 3). The 319 significantly proteins 
(up- and down-regulated) that were found by Benjamini-Hochberg analysis for early stage cervical cancer were applied to the IPA analysis 
tool. The pathway analysis resulted in the finding of the network “Cardiac Arrythmia, Cardiovascular Disease, Organismal Injury and 
Abnormalities” containing 29 out of the 319 significant proteins. The network itself consists of 35 proteins. The up-regulated proteins in 
early stage cervical cancer are marked red and those up-regulated in healthy epithelial cells are marked green. The intensity of the color (red 
or green) relates to fold-change. Interestingly, almost 50% (13 out of 29) of proteins identified were down-regulated. The symbols shown 
in the network are explained at http://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis.
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extracted from transcriptome data (Ojesina et al. [10]). 
Most of these overlapping proteins were found as 
highly differential in early stage cervical cancer when 
compared to the average gene expression level in the 
Ojesina et al. transcriptome data. This is illustrated in the 
Supplementary Figure 1 (“all-or-nothing” analysis) and 
Supplementary Figure 2A (Bonferroni analysis). In these 
heat maps it is shown that only four out of the 55 selected 
genes have low abundance, i.e. MPO (Supplementary 
Figure 1), CRNN, DSG1, and PDIA3 (Supplementary 
Figure 2A); CRNN and DSG in agreement with our 
proteomics study. The other 51 out of 55 genes were 
expressed at relatively high level, around 2log (FPKM) 
of 5. In general, many genes had undetectable transcript 
expressions, with 2log (FPKM) below -5 and those which 
were expressed had low values, i.e. 2log (FPKM) of 3 and 
4. To prove that genes were differentially expressed on 
protein level among highly expressed genes on RNA level, 
an analysis of gene expression of a background gene list 
was performed. This set was based on a selection of genes, 
corresponding to the list of the total identified proteins 
from LCM-derived samples (where 3,847 out of 4,138 
genes from single peptide identification with removal of 
decoys were found in the transcriptome sequencing data) 
showed that about 10% of the proteins were expressed 
at a very low level, see Supplementary Figure 2B. With 
this taken in account, for the early stage cervical cancer 
analysis using Bonferroni (Table 2B) and for both early 
(Supplementary Table 2) and late stage cervical cancer 
analysis (Supplementary Table 3) using Benjamini-
Hochberg the genes were significantly higher expressed 
(compared to background set, Wilcoxon rank-sum test, 
Figure 5: The 140 significantly proteins (up- and down-regulated) that were found by Benjamini-Hochberg analysis 
for late stage cervical cancer were applied to the IPA analysis tool. The pathway analysis resulted in the finding of the network 
“DNA Replication, Recombination, and Repair” containing 27 out of the 140 significant proteins. The network itself consists of 35 proteins. 
The up-regulated proteins in late stage cervical cancer are marked red and two proteins which were up-regulated in healthy epithelial cells 
are indicated with a green color. The intensity of the color (red or green) relates to fold-change. Proteins (n = 5) indicated with a red asterisk 
have been identified minimal once (99% protein- and 95% peptide probability with at least one peptide) by LCM, although not differential. 
The symbols shown in the network are explained at http://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis.
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p < 0.01) on transcriptome level. The early stage cervical 
cancer using the “all-or-nothing” analysis (Table 2A) and 
the late stage cervical cancer using the Bonferroni analysis 
(Supplementary Table 1) did not exhibit a significantly 
elevated RNA expression (p = 0.427 and p = 0.395, 
respectively). Heat maps, which were created for proteins 
analyzed by Benjamini-Hochberg for the comparison of 
individual early and late stage cervical cancer with healthy 
epithelium are represented in the Supplementary Figures 3 
and 4, respectively. 
Furthermore, mutated or expressed genes as listed 
by Ojesina et al. were compared for presence or absence 
in the total number of 2,989 proteins (identified with 
at least one peptide) identified by our LCM approach. 
The comparisons are compiled in Supplementary Table 4 
resulting in five overlapping proteins (CBFB, CEACAM5, 
MAPK1, PARN and TP63). For this panel, only CEACAM5 
was significantly different in abundance (p = 0.007) 
between early stage cervical cancer and healthy epithelium 
found by LCM and mass spectrometry.
DISCUSSION
The combination of laser capture microdissection 
and high-resolution mass spectrometry in tissue sections 
from squamous cell cervical cancer patients showed 
increased levels of proteins in tumor tissue versus healthy 
epithelium and stroma. Most striking was the increase in 
the members of the MCM family (up to 32-fold increase 
in abundance) and associated proteins. MCM proteins are 
Table 3: Overview of different types of analyses between early stage cervical cancer (EC) with healthy epithelium (H) 
and late stage cervical cancer (LC) with healthy epithelium
Type of analysis
EC versus H Threshold score 
by permutation 
(n = 10) related to 
EC versus H
Number of 
networks found 
above threshold 
score related to 
EC versus H
LC versus H
Threshold score by 
permutation (n = 10) 
related to LC versus H
Number of 
networks found 
above threshold 
score related to 
LC versus H
Number of 
differential 
proteins
IPA score***
Number of 
differential 
proteins
IPA score***
“all-or-nothing” 31 22 28.9 (18.1–28.9)* 0 - - - ** - **
Bonferroni 30 30 27.2 (17.8–27.2)* 1 13 8 11.8 (3.2–11.8)* 0
Benjamini-
Hochberg 319 43 41.4 (37.1–41.1)
* 2 140 48 40.8 (28.0–40.8)* 1
After applying the significant differential proteins analyzed by three analyses i.e. “all-or-nothing”, Bonferroni and Benjamini-Hochberg to IPA, the network scores were 
matched with a threshold score determined by permutation. This score was obtained after a permutation test (n = 10) according to the number of proteins identified by the three 
analyses and defined as the upper 95% CL of mean value. 
Network scores above this value were selected for discussion. 
*The lower and upper 95% CI of mean.
**Not applied for LC vs H analyzed by the “all-or-nothing” analysis.
***IPA scores were calculated by IPA using right-tailed Fisher’s Exact test.
Figure 6: Hierarchical clustering of fourteen proteins found by the IPA tool related to early stage cervical cancer (EC), late stage cervical 
cancer (LC) and healthy epithelium (HE) visualizes the heterogeneity among individual samples. For the early and late stage cervical cancer 
group, clustering of MCM proteins was readily observed and showed high similarity between samples. Interestingly, the MCM2, MCM3, 
MCM6 and MCM4, MCM7 clustered in two different clusters. For the healthy epithelium group, the result was different compared to early 
and late stage cervical cancer group in which only MCM6 from the MCM2-7 family clustered separately. The abundance levels of proteins 
were indicated with red (high) and black (low). Sample numbers correspond to those shown in Table 1.
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molecular motors that unwind duplex DNA and power 
fork progression during DNA replication. This process 
starts with initiation of DNA-replication occurring during 
S phase when two copies of each chromosome are present. 
Cdc6 and Cdt1 are then recruited by the origins recognition 
complex (ORC) and they in turn recruit the MCM complex 
to the ORC, forming the pre-RC and licensing the DNA for 
replication [26–28]. Because of its critical role during DNA 
replication, deregulation of MCM function contributes 
to human carcinogenesis [29]. Previous studies have 
shown that MCM proteins are highly expressed in various 
malignant human cancers and in cells at an early stage of 
malignant transformation [30, 31]. Members of the MCM 
family have also been described as diagnostic cancer 
markers, because they are not expressed in quiescent 
somatic cells that have been arrested in the G0 phase of the 
cell cycle. We and others hypothesize that up-regulation 
of MCM proteins is critical for tumor progression and that 
MCM proteins might serve as viable targets for anti-cancer 
therapy as well as molecular markers for diagnosis.
As mentioned above, we used three analysis 
techniques that were restrictive in finding differential 
Figure 7: Laser microdissected healthy epithelial cells were compared in a semi-quantitative way with early (A) and late (B) stage cervical 
cancer, a cervical cancer derived cell line (HeLa) and two cell lines that were derived from brain tumor (U87) and normal embryonal 
kidney tissue (HEK). Most of the fourteen differential proteins which were from the network behave similar between healthy epithelium 
and various tumor types, except for a few. The proteins PLAA, POLD1 and S100P were only observed in cervical cancer and HeLa digests 
when comparing to healthy epithelium (zero counts were converted into 0.125 to allow logarithm calculation). It was shown that MCM 
proteins in cervical cancer can have a 32-fold increase (2log fold-change of 5, e.g. MCM4) in abundance compared to healthy epithelium. 
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Table 4: Up- or down-regulated of all identified proteins calculated by 2log fold-changes (all compared to healthy 
epithelium) for LCM-derived cervical cancer cells and for HeLa cell line compared to other cell lines U87 and HEK293
A. Gene name EC (LCM)
LC 
(LCM) HeLa U87 HEK293
A-kinase anchor protein 13 AKAP13 3.1 3.2 4.3 0.0 0.0
Antigen peptide transporter 2 TAP2 2.8 2.8 3.0 –0.6 –0.6
DBIRD complex subunit ZNF326 A, BH ZNF326 2.9 3.2 5.0 0.0 0.0
E3 ubiquitin-protein ligase UBR4 BH UBR4 2.8 3.0 6.5 0.0 0.0
G patch domain and KOW motifs-containing protein GPKOW 2.7 2.7 5.2 0.0 0.0
Intercellular adhesion molecule 1 A, BH ICAM1 3.6 3.6 4.4 0.0 0.0
Leucine-rich repeat-containing protein 16A LRRC16A 2.7 2.6 4.0 0.0 0.0
Melanoma-associated antigen D2 MAGED2 2.8 2.5 4.4 0.0 0.0
Periostin POSTN 3.2 2.6 2.6 –1.4 –1.4
Phospholipase A-2-activating protein B, BH PLAA 3.2 2.8 5.1 –1.1 –1.1
Protein RCC2 BH RCC2 2.8 2.7 3.8 –2.1 –2.1
Protein S100-P A, B, BH S100P 2.9 2.6 3.9 0.0 0.0
Receptor-type tyrosine-protein phosphatase F BH PTPRF 3.3 3.0 2.7 –2.3 –2.3
RNA-binding protein 10 BH RBM10 3.0 2.5 4.2 –0.6 –0.6
Shootin-1 KIAA1598 2.6 2.6 4.5 –0.6 –0.6
Sterile alpha motif domain-containing protein 9 A SAMD9 3.8 3.9 2.8 0.0 0.0
Thrombospondin-1 THBS1 3.5 3.1 6.1 0.0 0.0
Ubiquitin-like protein ISG15 ISG15 2.5 3.4 3.4 0.0 0.0
Zinc finger RNA-binding protein BH ZFR 2.7 3.7 5.8 0.0 0.0
B. Gene name EC (LCM)
LC 
(LCM) HeLa U87 HEK293
Calcium-activated chloride channel regulator 4 CLCA4 2.8 3.3 0.0 0.0 0.0
Carcinoembryonic antigen-related cell adhesion 
molecule 5 A, BH CEACAM5 3.8 2.8 0.0 0.0 0.0
Cathelicidin antimicrobial peptide CAMP 3.8 2.7 0.0 0.0 0.0
Collagen alpha-1(XII) chain COL12A1 4.0 3.5 –2.1 –2.1 –2.1
Dimethylaniline monooxygenase [N-oxide-forming] 3 FMO3 3.5 2.6 0.0 0.0 0.0
E3 ubiquitin-protein ligase DTX3L A, BH DTX3L 3.7 3.2 0.0 0.0 0.0
Epithelial cell adhesion molecule EPCAM 3.2 3.2 0.0 0.0 0.0
Fibulin-2 FBLN2 3.1 3.0 0.0 0.0 0.0
HLA class II histocompatibility antigen, DRB1-16 beta 
chain A, BH HLA-DRB1 3.7 3.3 –0.6 –0.6 –0.6
HLA class II histocompatibility antigen, DRB1-7 beta 
chain HLA-DRB1 3.8 3.0 0.0 0.0 0.0
Myeloperoxidase A MPO 5.0 3.6 0.0 0.0 0.0
Poly [ADP-ribose] polymerase 9 A, BH PARP9 3.7 2.6 0.0 0.0 0.0
Stimulator of interferon genes protein TMEM173 3.0 2.8 0.0 0.0 0.0
Transgelin TAGLN 3.5 2.9 –1.7 –1.7 –1.7
Panel A represents nineteen up-regulated proteins found in the early and late stage cervical cancer of LCM-derived cells and 
HeLa only. Panel B shows fourteen significant proteins exclusively found by LCM. For both panels, the following criterion 
was used: 2log fold-change ≥ 2.5, zero counts were converted to 0.125 to enable log calculations. Proteins indicated with 
(superscripts) A, B and BH were found by the “all-or-nothing”, Bonferroni and Benjamini-Hochberg correction for multiple 
testing, respectively.
EC: early stage cervical cancer.
LC: late stage cervical cancer.
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Figure 8: Example of targeted mass spectrometry by PRM. Total amount (in nanograms) of the proteins MCM3, CEACAM5, 
S100P and ICAM1 were determined in digests of whole tissue lysates. Total tissue areas (mm2) and UV peak areas (mAU*min) were 
applied on top of the figure to estimate the amount of tissue used. Blue, red and green bars correspond to early stage cancer, late stage 
cancer and healthy samples, respectively.
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proteins. In addition, we used an extra threshold by a 
permutation approach in the protein network finding. 
Using these restrictive analyses, we believe to be confident 
in finding the most discriminative proteins and networks 
of these proteins. Apparently, the differences between 
cervical cancer cells and healthy epithelial cells were that 
large that we were able to find relatively high number of 
proteins that fulfill these restrictions.
Our IPA analysis indicated that the biological 
interactions of the 30 proteins identified by Bonferroni 
related to cervical cancer correlated to the network “DNA 
Replication, Recombination, and Repair”. The same 
network was assigned to analyses determined by Benjamini-
Hochberg. Remarkably, another network “Cardiac 
Arrhythmia, Cardiovascular Disease, Organismal Injury and 
Abnormalities” that was found with the proteins from the 
Benjamini-Hochberg analysis was filled with a high number 
of down-regulated proteins. Most probably cervical specific 
proteins are lost in early cancer cells during the tumor 
oncogenesis. For diagnostic purposes, elevation of a protein 
marker could be more applicable than down-regulated 
proteins. 
We found nineteen proteins (Table 4) that were 
up-regulated in cervical cancer (early and late stage) 
tissue and HeLa when compared to healthy epithelium 
from controls obtained by LCM. Some of these proteins 
might be cervical cancer-related, since they were not up-
regulated in cells from other non-cervical HEK and U87 
cell cultures but only in the HeLa cell line. Nevertheless, 
more cervical cancer cell lines ought to be investigated to 
confirm this. One of these proteins is CEACAM5, a protein 
with HPV integration sites that was also found by Ojesina 
et al. [10] to be highly expressed (Supplementary Figure 
1). CEACAM5 is related to cell-adhesion molecules and 
belongs to the carcinoembryonic antigen (CEA) gene 
family. It is strongly expressed in epithelial cells and 
known as a tumor marker for early detection of recurrent 
disease due to its expression in several adenocarcinomas 
(e.g. colon, lung, breast, ovarian) [32], however, there is 
no literature related to cervical cancer. 
The coding mutation in ERBB2 described by 
Ojesina et al. [10] as being specific for cervical cancer 
could not be detected by our LCM approach. MAPK1, 
also described as being specific for cervical cancer was 
detected. However, the abundance level did not change in 
cervical cancer compared to healthy epithelial or stroma 
cells according to our analysis. S100P was found to be 
up-regulated in cervical cancer tissue from early and late 
stage patients as well as in HeLa cells. It was not found 
in healthy epithelium, stroma, U87 and HEK293 cells, 
although it is overexpressed in several other cancers 
[33]. S100P is a member of the S100 protein family that 
is characterized by its calcium-binding properties due to 
structural motifs containing 2 EF-hand domains. S100P 
was first isolated from human placenta and has a crucial 
role in several biological functions; however, its exact 
function in cervical cancer remains unclear [33, 34]. 
Quantitative proteomics by PRM was used to confirm 
the observation of four proteins. It was shown that full 
agreement was obtained on digests of whole tissue lysates. 
As sensitivity is in PRM much better than in shotgun 
proteomics, an almost all-or-nothing difference was 
observed between the cancer and healthy samples. The 
difference for MCM3 was detectable for all samples with 
roughly two to three orders of magnitude. 
National population-based cervical cancer screening 
programs have reduced the incidence of cervical cancer 
significantly in the western world [35]. However, in 
both the technical aspects and performance of different 
screening test there is room for improvement. The most 
widely used cervical cancer screening test is cytology-
based testing. Primary screening for cervical cancer 
is currently changing in many countries including the 
Netherlands. HrHPV testing is becoming the preferred 
primary screening test over cytology. By hrHPV testing 
the sensitivity for detecting premalignant lesions is much 
higher [36–38]. Because of this increased sensitivity, more 
CIN2+ lesions will be detected and less carcinomas will 
be missed. A disadvantage of the hrHPV test for primary 
screening is the lower specificity of this test, resulting 
from detection of women with transient HPV infection 
who will not develop (premalignant) cervical cancer. 
To prevent unnecessary referral to the gynecologist and 
associated high costs, there is a need for risk stratification 
by triage testing of hrHPV positive women and the four 
selected proteins for PRM might help in that respect.
Simple, more specific biomarkers for cervical cancer 
and its precancerous stages are required that can be used on 
e.g. liquid-based cytology (LBC) samples. These samples 
used for routine screening in a precancerous stage could 
be used for targeting differentially expressed proteins in a 
multiplexed manner (e.g. >50 proteins). LBC samples can 
be related much more directly to cervical tissue because 
they are less complex compared to e.g. sera where the 
extreme range of different serum proteins puts limits on the 
detection of proteins in the ng/mL range without the use of 
antibody or other new affinity enrichment steps.
In conclusion, we have shown that LCM proteomics 
with high-resolution mass spectrometry is a viable 
approach to detect differences in individual protein levels 
in tissues of early stage squamous cell cervical cancer 
patients compared to healthy control tissue. For four 
proteins we were able to confirm in a quantitative way 
these rather large differences in protein levels. In addition, 
we have found two significant differential networks. A 
down-regulated network that probably shows the loss of 
cervical specific proteins in cancer cells and a highly-up-
regulated network that relates to a cancer mechanism that 
involves proliferation and progression in cervical cancer. 
These networks can be used as sources for diagnostics and 
will add to understanding the early processes in cervical 
cancer. 
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MATERIALS AND METHODS
Sample procurement
All patients referred to the outpatient clinic of 
the University Medical Center Groningen (UMCG) 
with squamous cervical cancer were routinely asked to 
participate in our ongoing ‘Methylation study’ which has 
been approved by the Institutional Review Board (IRB) 
of the UMCG. Cervical tissue and clinicopathologic data 
were prospectively collected and stored in our tissue 
bank. Within our ‘Methylation study’ tissue samples and 
clinicopathologic data that were collected from normal 
cervical tissues, were also collected from patients who 
planned to undergo a hysterectomy for non-malignant 
reasons. All cervical tissues that were used for the healthy 
control group was judged as histopathological normal. For 
determination of the percentage of tumor in the cancer 
specimen, 4 μm sections were cut and haematoxylin & 
eosin (HE) stained. Only specimens with more than 70% 
tumor were used. For LCM, we selected frozen tissue of 
22 SCC patients and from thirteen controls (Table 1). The 
median age of the cervical cancer patients was 55 years 
(IQR 44–75) and for the patients with normal cervices 
43 years (IQR 41–50). The stage of SCC patients was: 3 
(14%) FIGO stage IB1, 5 (23%) FIGO stage IB2, 3 (14%) 
FIGO stage IIB, 2 (9%) FIGO stage IIIA, 6 (27%) FIGO 
stage IIIB and 3 (14%) FIGO stage IV. FIGO stages I–
II and III–IV were defined as early stage and late stage 
cervical cancer, respectively. All tissues were primary 
tumors and patients did not receive neoadjuvant therapy.
LCM
Areas for LCM were selected on HE-stained 
cryosections. Cryosections of 10 µm were prepared from 
each of the eleven early and eleven late stage cervical 
cancer, and the thirteen healthy cervical tissue samples. 
The sections were mounted on polyethylene naphthalate 
(PEN)-covered glass slides (Carl Zeiss, Zwijndrecht, the 
Netherlands). An area corresponding to approximately 
8,000 cells was microdissected. We calculated the number 
of cells by assuming an average volume of 10  × 10 × 10 µm 
for one cell. The tissue pieces were collected in 20 μL 0.1% 
Rapigest SF detergent (Waters, Milford, MA, USA) and 
reduced using 4.7 mM dithiothreitol at 60° C for 30 minutes 
followed by alkylation using 16.9 mM iodoacetamide in 
the dark at room temperature for 30 minutes. Subsequently, 
the tissue pieces were enzymatically digested by adding 2 
µL trypsin (Mass Spectrometry grade, 100 μg/mL in 3 mM 
Tris-HCl, pH 8.8) at 37º C overnight.
Protein identification by nano-LC-MS/MS
Online nano-LC-ESI-MS/MS using an application of 
a shotgun proteomics workflow was used for identification 
of tryptic peptides. A digested peptide mixture equivalent 
to 8,000 cells was separated on an Ultimate 3000 HPLC 
system (Thermo Fisher Scientific, Germering, Germany) 
and subsequently online measured in an Orbitrap Fusion 
mass spectrometer (Thermo Fisher Scientific, San Jose, 
CA, USA) in the data-dependent acquisition mode. 
Samples were loaded on to a trap column (PepMap C18, 
300 µm ID, 5 mm length, 5 µm particle size, 100 Å pore 
size; Thermo Fisher Scientific), washed and desalted 
for 8 minutes using 0.1% trifluoroacetic acid as loading 
solvent at a flow rate of 20 µL/min. The trap column was 
switched in-line with the analytical column (PepMap C18, 
75 µm ID  × 500 mm, 2 µm particle size and 100 Å pore 
size, Thermo Fisher Scientific) and peptides were eluted 
with a 90-minute acetonitrile gradient ranging from 3% to 
30% (and formic acid concentration from 0.1% to 0.08%, 
respectively). All LC solvents were purchased at Biosolve 
(Valkenswaard, the Netherlands). Column flow rate was 
set to 250 nL/min, and eluting peptides were measured 
at 214 nm in a 3 nL nano flow cell (Thermo Fisher 
Scientific), online coupled to the mass spectrometer. For 
electrospray ionization nano ESI emitters (New Objective, 
Woburn, MA, USA) were used and a spray voltage of 
1.7 kV was applied. For MS detection, a data-dependent 
acquisition method was used with a survey scan from 
350–1650 Th at 120,000 resolution (AGC target 400,000) 
and consecutively isolated and fragmented by collisional 
induced dissociation (CID) at 35% normalized collision 
energy (AGC target 10,000) of the most abundant 
precursors in the linear ion trap until a duty cycle time of 
3 seconds was reached (‘Top Speed’ method). Precursor 
masses that were selected once for MS/MS were excluded 
from further fragmentation for the next 60 seconds. 
Proteins from the LCM-derived samples were 
assigned by exporting features, for which MS/MS spectra 
were recorded, using the ProteoWizard software (version 
3.0.9248; http://proteowizard.sourceforge.net). Resulting 
.mgf files were submitted to Mascot (version 2.3.01, 
Matrix Science, London, UK) and applied to the human 
database (UniProtKB/Swiss-Prot, version 2013_07, human 
taxonomy, 20,265 entries) for protein identifications 
assuming trypsin digestion and applying the following 
parameters: fragment ion mass tolerance of 0.50 Da, 
parent ion mass tolerance of 10 ppm, maximum number 
of missed cleavages of two. Oxidation of methionine was 
specified in Mascot as a variable modification, while 
carbamidomethylation of cysteine was set as a fixed 
modification. Scaffold (version 4.7.2, Proteome Software 
Inc., Portland, OR) was used to summarize and filter the 
MS/MS-based peptide data from all Mascot searches. The 
number of proteins was derived from the peptide data 
according to the following criteria. Peptide identifications 
needed to have more than 95% probability as specified by 
the Peptide Prophet algorithm. Protein identifications had 
to have more than 99% probability and contain at least one 
peptide identified. 
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Data analysis
Technical and methodological reproducibility 
was determined by performing the measurements in 
triplicate and doing the entire experiment (microdissection 
and tryptic digestion) also in triplicate. For technical 
reproducibility, a tryptic digested tissue lysate was used, 
while for methodological reproducibility an LCM-derived 
sample was taken and measured. A diagram illustrating 
the experimental design is shown in Figure 9. For both 
reproducibility types, the total number of overlapping 
identified proteins was analyzed by Scaffold and 
eventually the percentage was used as a readout. For both 
reproducibility types an overlap greater than 50% was 
indicated as acceptable [39, 40]. 
A volcano plot was created to determine changes in 
protein abundances indicated as 2log fold-changes between 
individual early and late stage cervical cancer with the 
healthy epithelium group (p < 0.05). The 2log fold-changes 
were calculated based on comparison of the individual 
early and late stage cervical cancer with healthy epithelium 
according to spectral counts (zero counts were converted to 
0.125 to enable log calculations). Three different analysis 
methods were chosen for comparison of the early stage 
cervical cancer with the healthy epithelium and late stage 
cervical cancer group with the healthy epithelium group. 
Two stringent analyses were used i.e. an analysis based 
on an “all-or-nothing” criteria and second a Bonferroni 
analysis to correct for multiple testing, and third a less 
stringent correction for multiple testing i.e. Benjamini-
Hochberg. The “all-or-nothing” analysis was deemed 
discriminative when 1) a protein was not identified in 
healthy epithelium and stroma and when 2) a protein was 
at least identified in seven out of the eleven early stage 
cervical cancer subjects. In addition, the identified proteins 
from early stage cervical cancer were allowed to be present 
in late stage cervical cancer. We have chosen for these 
three analyses to classify in a restrictive way (Bonferroni) 
and a more relaxed analysis (Benjamini-Hochberg), and 
the “all-or-nothing” analysis that offers more possibilities 
to handle missing values in mass spectrometry. The 
differentially abundant proteins found by these three 
analysis methods, have been introduced into pathway 
analysis using the IPA software [41]. Data were entered 
into the IPA tool to assign the differentially expressed 
proteins to different network interactions according to 
their respective significance levels to fit in that network. 
A permutation test was performed to determine a threshold 
score by selection of random 31 (comparable numbers with 
those analyzed by the “all-or-nothing” criteria), 30 and 13 
proteins (comparable numbers with those analyzed by 
Bonferroni analysis between individual early and late stage 
cervical cancer with healthy epithelium, respectively), 319 
and 140 proteins (comparable numbers with those analyzed 
by Benjamini-Hochberg between individual early and late 
stage cervical cancer with healthy epithelium, respectively) 
that were extracted from the UniProt database (uniprot_
sprot_HUMAN_v151112; 20194 entries). The test was 
repeated ten times and from the networks with highest 
score (as calculated by IPA using right-tailed Fisher’s Exact 
test) the mean value of the ten repeats was calculated and 
subsequently the lower- and upper 95% confidence level 
(Cl) of the mean were calculated. Network scores which 
exceeded the 95% Cl of the mean threshold (assumed 
as background) were taken into account as confidential 
differential.
To determine the heterogeneity among patients, a 
hierarchical clustering analysis was performed of fourteen 
differential IPA classified proteins that belonged to 
Bonferroni analysis when comparing early stage cervical 
cancer with healthy epithelium. The IPA classified proteins 
were clustered individually in samples from the groups early 
Figure 9: Experimental design of technical and methodological reproducibility.
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and late stage cervical cancer and healthy epithelium. For 
hierarchical clustering analysis PermutMatrix 1.9.3. was 
used (http://www.atgc-montpellier.fr/permutmatrix) selecting 
the Euclidean distance for dissimilarity, Wards’ method, as a 
cluster method and Bipolarization seriation [42, 43]. 
Confirmation by PRM mass spectrometry
Identical numbers of the tissue samples (Table 1) 
were measured by PRM to quantify MCM3, CEACAM5, 
S100P and ICAM1 in digests of whole tissue lysates 
using stable isotope-labeled (SIL) peptides purchased 
from Pepscan BV (Lelystad, the Netherlands). A subset 
of nine peptides were selected to be quantified by PRM 
(Supplementary Table 5). Collected tissue pieces were 
compiled in 200 µL 0.1% Rapigest SF detergent, sonicated 
for 3 minutes using a horn sonifier bath (Ultrasonic 
Disruptor Sonifier II, Bransons Utrasonics, Danbury, 
CT, USA) at 85% amplitude and heated for 5 minutes 
at 99° C for protein denaturation. Subsequently, 50 out 
of the 200 µL tissue lysates were each spiked with 10 
fmol of the SIL peptides prior to enzymatic digestion. 
Samples were subsequently digested by adding 2 µg 
trypsin at 37° C overnight. One microliter of each sample 
was measured by PRM, performed on an Orbitrap 
Fusion instrument according to our previous work [44]. 
Analytical parameters such as linearity, LOD and LOQ 
were determined. For reproducibility, CVs were calculated 
for each serial dilution (0, 0.625, 1.25, 2,5, 5, 10 and 20 
fmol/uL) using triplicate measurements. 
Comparison of protein profiles in LCM-derived 
early stage cervical cancer tissue with HeLa, U87 
and HEK293 cell lines
The identified proteins from the “all-or-nothing”, 
Bonferroni and Benjamini-Hochberg analysis (comparison of 
the early stage cervical cancer tissue with healthy epithelium 
group only) were compared with proteins identified in the 
cervical cancer derived HeLa cell line and two other cell 
lines that are unrelated to cervical cancer (U87; primary 
glioblastoma and HEK293; Human Embryonic Kidney 
cell line) by calculating 2log fold-changes related to LCM-
derived healthy cervical epithelium. Proteins were filtered 
with the following criterion for each individual group: 2log 
fold-change relative to healthy epithelium > 1. For HeLa, 
a standard protein digest (catalog no. 88328, Thermo 
Scientific, Landsmeer, the Netherlands) was used. From 
U87 and HEK293 cell lines 106 cells of each cell type were 
digested according to a protocol as recommended by Thermo 
Scientific (catalog no. 90110). For all three cell lines one 
µg of each digest was analyzed by nano-LC-Orbitrap MS/
MS. The IPA classified proteins were compared with their 
abundances in the two cervical cancer groups (early and late 
stage) and in the various cell lines. Scaffold perSPECtives 
viewer (version 2.1.0, Proteome Software Inc., Portland, 
OR) was used for visualization of proteins found in cervical-
derived tissue by using LCM simultaneously with results 
obtained from these three cell lines.
Comparison to existing genomic data
Proteomic data were compared to transcriptome 
data published by Ojesina et al. [10]. Transformed 2log 
expression values were extracted from the transcriptome 
sequencing data of tumor samples consisting of squamous 
cell carcinoma and adenocarcinoma. These genomic data 
contained no expression data information about healthy 
tissue as indicated by Ojesina et al. and therefore no 
comparisons could be made to the healthy controls in 
our study. Heat maps were created of the proteins from 
the three analyses performed in this study (Table 2A, 2B; 
Supplementary Tables 1–3). Genes were selected only from 
the genomic analysis that overlapped with genes identified 
with the proteomic approach (set of 4,138 proteins with the 
removal of decoys). For this selection of genes, an average 
expression level (across all samples) was defined. Using 
Wilcoxon rank-sum test, the average mRNA expression 
levels of genes identified as differentially expressed 
in proteome analysis (represented in heat maps) was 
evaluated if this was different from the average mRNA 
expression products of other genes that were identified on 
protein level (Significance level p < 0.01).
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